Our Parkinson's Place: New biomarker assay offers hope for Parkinson's patients

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Wednesday, February 10, 2016

New biomarker assay offers hope for Parkinson's patients

February 10, 2016

EU researchers have developed a Parkinson's disease biomarker assay that could lead to early diagnoses and faster, more effective treatments.

Developed through the EU-funded BIOMARKERS FOR PD project, the innovation has the potential to become the first biochemical biomarker assay capable of reflecting the underlying pathophysiology of the disease. A key component of the project has been to evaluate the business opportunities and future development path for such Parkinson's disease biomarkers.

A healthcare priority for Europe

Parkinson's disease is one of the most prevalent neurodegenerative disorders. Around the world, more than 4.6 million people aged 50 and over currently suffer from the condition, and the World Health Organisation estimates that this number will more than double by 2030.

The condition exacts a heavy social and economic cost. It can significantly impact the quality of life, not only for patients but also for families, friends and carers. In financial terms, it has been estimated that the annual healthcare bill for treating Parkinson's disease in Europe tops EUR 14 billion.

Improving the treatment of Parkinson's disease is therefore a healthcare priority for Europe and a key opportunity for European SMEs and high tech businesses in the healthcare sector. At present only symptomatic therapies are available, and the disease is often difficult to diagnose. Misclassification, especially in early Parkinson's disease, occurs frequently. High sensitivity and specificity can only be obtained at specialised centres and after several years of follow-up.

Developing an effective Parkinson's biomarker

There is therefore a huge unmet market and need for treatments that slow or halt disease progression. One area that has shown promise has been the achievement of early diagnoses, which can improve patient outcomes.

This has been the objective of the BIOMARKERS FOR PD project. The development of an effective Parkinson's disease biomarker assay would help clinical practitioners identify the onset of the disease earlier than previously possible and thus enable them to put in place effective treatments.

Biomarkers are used in clinical practice to describe both normal and pathological conditions. They can also have a prognostic or a predictive power, and are therefore increasingly used in medicine. Clinical validation of biomarkers is vital for the development of new diagnostics, and this is where the BIOMARKETS FOR PD project has sought to make a difference.

Clinical validation of existing potential biomarkers has also been sought. The project team is looking for evidence of high analytical validity; appropriate sensitivity and specificity; and clinical validity/utility. Results will ultimately facilitate the entry of improved diagnostics in the clinic and the market and enhance the growth potential of high tech SMEs operating in the healthcare sector.

'We are grateful for the support from EU,' says Dr. Gunilla Osswald, CEO of project coordinator BioArctic Neuroscience AB. 'The development of a sensitive and specific biomarker that also could mirror the treatment effect would make an enormous advantage in the development of new disease modifying therapeutics.' The BIOMARKERS FOR PD project is scheduled for completion in March 2016.